Natco Pharma
Pharmaceuticals | |
| Founded | 1981 |
|---|---|
| Founder | VC Nannapaneni |
| Headquarters | , India |
Area served | Global |
Key people | VC Nannapaneni (Chairman and MD)[1] Rajeev Nannapaneni (CEO and Vice Chairman)[2] |
| Revenue |  ₹2,811 crore (US$350 million) (FY23)[3] |
| ₹715 crore (US$90 million) (FY23)[3] | |
| Website | natcopharma.co.in |
Natco Pharma is an Indian multinational
active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services.[4] It is a major producer of branded oncology medicines[5] and hepatitis C drugs.[6] The company specialises in producing complex medicines at affordable prices.[7][8] In 2019, Natco launched its crop health sciences division.[9][10]
History
- In 2003, Natco Pharma launched Veenat, a generic version of Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.[11]
- In 2012, Natco Pharma obtained Nexavar.[6]
- In the United States, it launched Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[11]
- In 2015, Natco Pharma started production of Sofosbuvir in Nepal.[12]
- In 2016, Natco Pharma launched the first Tamiflu capsule in the US market.[13]
- In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.[14]
- In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[15]
External links
References
- ^ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
- ^ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
- ^ a b "Natco Pharma posts 345% sequential growth in Q4 PAT to ₹276 crore". Mint. 29 May 2023. Retrieved 27 June 2023.
- ^ "Our Business | Natco Pharma". Retrieved 25 April 2022.
- ^ "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
- ^ a b "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
- ^ PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
- ^ Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
- ^ "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
- ^ Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
- ^ a b "Niche Play". Business Today. Retrieved 19 April 2020.
- ^ "Natco Pharma History | Natco Pharma Information". The Economic Times. Retrieved 3 February 2022.
- ^ "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
- ^ "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price". Firstpost. 10 May 2017. Retrieved 31 July 2020.
- ^ "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.
